, Chung, , Hahm, , and Lee: Risk Factors Associated With Colistin-Resistant Acinetobacter baumannii Infection

Hae-Sun Chung1,2*Chorong Hahm1,3*Miae Lee1,2

1Department of Laboratory Medicine, Ewha Womans University College of Medicine, Seoul, Korea
2Ewha Education and Research Center for Infection, Ewha Womans University Medical Center, Seoul, Korea
3Department of Laboratory Medicine, Eone Laboratories, Incheon, Korea


*Corresponding author: E-mail: miae@ewha.ac.kr


ABSTRACT

Acinetobacter baumannii is an important cause of healthcare-associated infections and is resistant to almost all antimicrobial agents, with strains recently reported to be resistant to colsitin. In this study, we aimed to identify the risk factors associated with colistin-resistant A. baumannii infections by comparing colistin-resistant and -susceptible A. baumannii isolates. We retrospectively reviewed the medical records of 51 and 100 cases in which colistin-resistant and -susceptible A. baumannii were isolated, respectively. Univariate analysis showed that compared with patients with colistin-sensitive infections, patients with colistin-resistant A. baumanni infections had a combined pulmonary disease (P = 0.017), were admitted to intensive care unit (P = 0.020), and had prior mechanical ventilation (P = 0.003), tracheostomy (P = 0.043), percutaneous drainage (P = 0.070), hemodialysis (P = 0.002); use of colistin (P = 0.000), carbapenem (P = 0.000), and teicoplanin (P = 0.004); and co-infection (P = 0.035). Multivariate analysis indicated that eight variables were related to the likelihood of colistin-resistant A. baumanni infections: use of teicoplanin (Odds ratio [OR]: 3.140, 95% confidence interval [CI]: 0.529–18.650), prior hemodialysis (OR: 2.722, 95% CI: 0.851–8.709), combined pulmonary disease (OR: 2.286, 95% CI: 0.998–5.283), prior use of carbapenem (OR: 0.199, 95% CI: 0.863–5.603), co-infection (OR: 1.706, 95% CI: 0.746–3.898), prior mechanical ventilation (OR: 1.614, 95% CI, 0.684–3.809), intensive care unit admission (OR: 1.387, 95% CI: 0.560–3.435), and prior tracheostomy (OR: 1.102, 95% CI: 0.344–3.527); however, no statistical differences were observed. Although colistin use could not be proven in multivariate analysis, the possibility of being a risk factor cannot be ruled out.

Keywords



Figures & Tables

Table 1. Antimicrobial resistance of colistin-resistant A. baumannii and colistin-susceptible A. baumannii groups

Antimicrobial

Colistin-resistant group (n=51)

Colistin-susceptible group (n =100)

P-value

No. (%)

No. (%)

Amikacin

45 (88.2)

55 (55.0)

0.000

Ampicillin/sulbactam

33 (64.7)

51 (51.0)

0.000

Cefepime

47 (92.2)

60 (60.0)

0.000

Cefotaxime

50 (98.0)

60 (60.0)

0.000

Ceftazidime

47 (92.2)

60 (60.0)

0.000

Ciprofloxacin

46 (90.2)

58 (58.0)

0.000

Gentamicin

46 (90.2)

56 (56.0)

0.000

Imipenem

51 (100.0)

58 (58.0)

0.000

Meropenem

48 (94.1)

59 (59.0)

0.000

Minocycline

23 (45.1)

25 (25.0)

0.004

Piperacillin

49 (96.1)

62 (62.0)

0.000

Ticarcillin/Clavulanic

48 (94.1)

59 (59.0)

0.000

Trime thoprim/sulfamethoxazole

44 (86.3)

55 (55.0)

0.000